TARA - NASDAQ

Protara Therapeutics, Inc.

TARA·NASDAQ

$4.22

-1.2%

HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$162.85M

EPS-1.3400

P/E Ratio-3.15

Earnings Date07/30/2026

tara

Net Cash Provided by Financing Activities

Last Annual Value

82.72M

3-Year CAGR

873%

5-Year CAGR

-15%

10-Year CAGR

86%

Adjust for Inflation

Protara Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

TARA · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Protara Therapeutics, Inc. NASDAQ:TARA	82.72M	N/A	N/A	82.0%
Assembly Biosciences, Inc. NASDAQ:ASMB	174.67M	132.9%	26.9%	102.2%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	77.43M	N/A	4.9%	16.5%
Immuneering Corporation NASDAQ:IMRX	226.58M	99.7%	9.4%	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	594.00K	-53.6%	-71.3%	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	24.82M	-43.3%	-31.5%	N/A
Invivyd, Inc. NASDAQ:IVVD	215.63M	490.9%	-20.1%	N/A
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO	88.33M	24.1%	N/A	N/A
Codexis, Inc. NASDAQ:CDXS	27.93M	50.7%	49.3%	N/A
OmniAb, Inc. NASDAQ:OABI	27.91M	N/A	23.5%	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	70.75M	69.3%	16.6%	70.7%

Protara Therapeutics, Inc. Fair Value Envelope

TARA · NASDAQ

Our analysis suggests that TARA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.22, this represents a potential HIDDEN relative to our calculated worth for Protara Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.22

Related Guides

Blog Categories

Continue your TARA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.